WO2008033464A3 - Azetidinone derivatives for the treatment of disorders of the lipid metabolism - Google Patents
Azetidinone derivatives for the treatment of disorders of the lipid metabolism Download PDFInfo
- Publication number
- WO2008033464A3 WO2008033464A3 PCT/US2007/019930 US2007019930W WO2008033464A3 WO 2008033464 A3 WO2008033464 A3 WO 2008033464A3 US 2007019930 W US2007019930 W US 2007019930W WO 2008033464 A3 WO2008033464 A3 WO 2008033464A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- lipid metabolism
- disorders
- treatment
- azetidinone
- azetidinone derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Abstract
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2009528293A JP2010503677A (en) | 2006-09-15 | 2007-09-13 | Azetidinone derivatives for treating disorders of lipid metabolism |
MX2009002921A MX2009002921A (en) | 2006-09-15 | 2007-09-13 | Azetidinone derivatives for the treatment of disorders of the lipid metabolism. |
CA002663502A CA2663502A1 (en) | 2006-09-15 | 2007-09-13 | Azetidinone derivatives and methods of use thereof |
EP07838185A EP2061792A2 (en) | 2006-09-15 | 2007-09-13 | Azetidinone derivatives for the treatment of disorders of the lipid metabolism |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US84507506P | 2006-09-15 | 2006-09-15 | |
US60/845,075 | 2006-09-15 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2008033464A2 WO2008033464A2 (en) | 2008-03-20 |
WO2008033464A3 true WO2008033464A3 (en) | 2008-05-15 |
Family
ID=39145026
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2007/019930 WO2008033464A2 (en) | 2006-09-15 | 2007-09-13 | Azetidinone derivatives for the treatment of disorders of the lipid metabolism |
Country Status (9)
Country | Link |
---|---|
US (1) | US7884080B2 (en) |
EP (1) | EP2061792A2 (en) |
JP (1) | JP2010503677A (en) |
CN (1) | CN101583612A (en) |
AR (1) | AR063219A1 (en) |
CA (1) | CA2663502A1 (en) |
MX (1) | MX2009002921A (en) |
TW (1) | TW200819450A (en) |
WO (1) | WO2008033464A2 (en) |
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2009002918A (en) * | 2006-09-15 | 2009-03-31 | Schering Corp | Azetidinone derivatives and methods of use thereof. |
CN101541795A (en) * | 2006-09-15 | 2009-09-23 | 先灵公司 | Spiro-condensed azetidine derivatives useful in treating pain, diabetes and disorders of lipid metabilism |
MX2009002922A (en) * | 2006-09-15 | 2009-04-01 | Schering Corp | Azetidine and azetidone derivatives useful in treating pain and disorders of lipid metabolism. |
WO2008033431A1 (en) * | 2006-09-15 | 2008-03-20 | Schering Corporation | Spirocyclic azetidinone derivatives for the treatment of disorders of lipid metabolism, pain, diabetes and other disorders |
EP2025674A1 (en) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituted tetra hydro naphthalines, method for their manufacture and their use as drugs |
US20090092693A1 (en) * | 2007-10-05 | 2009-04-09 | Mady Attila | Platelet manipulation to prevent and treat endovascular disease and its sequelae, to prevent and treat arrhythmias and to prevent malignancy |
CA2723358A1 (en) * | 2008-05-05 | 2009-11-12 | Allison B. Reiss | Method for improving cardiovascular risk profile of cox inhibitors |
MX2011003015A (en) | 2008-09-18 | 2011-11-18 | Univ Northwestern | Nmda receptor modulators and uses thereof. |
WO2010141817A1 (en) | 2009-06-05 | 2010-12-09 | Janssen Pharmaceutica Nv | Heteroaryl-substituted spirocyclic diamine urea modulators of fatty acid amide hydrolase |
US8951968B2 (en) | 2009-10-05 | 2015-02-10 | Northwestern University | Methods of treating depression and other related diseases |
CN102933226A (en) | 2010-02-11 | 2013-02-13 | 西北大学 | Secondary structure stabilized nmda receptor modulators and uses thereof |
KR101692275B1 (en) | 2010-02-11 | 2017-01-04 | 노오쓰웨스턴 유니버시티 | Secondary structure stabilized nmda receptor modulators and uses thereof |
EP2575821B1 (en) | 2010-05-26 | 2015-08-12 | Satiogen Pharmaceuticals, Inc. | Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions |
WO2011157827A1 (en) | 2010-06-18 | 2011-12-22 | Sanofi | Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases |
TWI622573B (en) | 2010-11-05 | 2018-05-01 | 拜耳知識產權公司 | Process for the preparation of substituted n-(benzyl)cyclopropanamines by imine hydrogenation |
CN103958495B (en) | 2011-06-09 | 2018-06-22 | 理森制药股份公司 | The compound of conditioning agent as GPR-119 |
EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
ES2633766T3 (en) | 2011-10-28 | 2017-09-25 | Lumena Pharmaceuticals Llc | Bile acid recycling inhibitors for the treatment of pediatric cholestatic liver diseases |
MX363161B (en) | 2011-10-28 | 2019-03-13 | Lumena Pharmaceuticals Inc | Bile acid recycling inhibitors for treatment of hypercholemia and cholestatic liver disease. |
KR102085535B1 (en) * | 2012-04-26 | 2020-03-06 | 바이엘 크롭사이언스 악티엔게젤샤프트 | Process for preparing n-(5-chloro-2-isopropylbenzyl)cyclopropanamine |
TWI598098B (en) | 2012-09-27 | 2017-09-11 | 興和股份有限公司 | Therapeutic agent for dyslipidemia |
LT3514158T (en) | 2013-01-29 | 2023-02-10 | Aptinyx Inc. | Spiro-lactam nmda receptor modulators and uses thereof |
EA201591405A1 (en) | 2013-01-29 | 2017-05-31 | Аптиникс Инк. | SPIROLACTAM NMDA-RECEPTOR MODULATORS AND THEIR APPLICATION |
MX2015009778A (en) | 2013-01-29 | 2016-02-09 | Aptinyx Inc | Spiro-lactam nmda receptor modulators and uses thereof. |
AU2014212487C1 (en) | 2013-01-29 | 2018-10-25 | Aptinyx, Inc. | Spiro-lactam NMDA receptor modulators and uses thereof |
EP2951182B1 (en) | 2013-01-29 | 2020-03-18 | Aptinyx Inc. | Spiro-lactam nmda receptor modulators and uses thereof |
MX2015013196A (en) | 2013-03-15 | 2016-04-15 | Lumena Pharmaceuticals Inc | Bile acid recycling inhibitors for treatment of barrett's esophagus and gastroesophageal reflux disease. |
KR20160002773A (en) | 2013-03-15 | 2016-01-08 | 루메나 파마수티컬즈, 인코포레이티드 | Bile acid recycling inhibitors for treatment of primary sclerosing cholangitis and inflammatory bowel disease |
WO2015111971A1 (en) * | 2014-01-23 | 2015-07-30 | 동국대학교 산학협력단 | Pharmaceutical composition containing gpr119 ligand as active ingredient for preventing or treating non-alcoholic fatty liver disease |
WO2017070680A1 (en) | 2015-10-22 | 2017-04-27 | Cavion Llc | Methods for treating angelman syndrome and related disorders |
MX2018014202A (en) | 2016-05-19 | 2019-06-20 | Aptinyx Inc | Spiro-lactam nmda receptor modulators and uses thereof. |
WO2017201285A1 (en) | 2016-05-19 | 2017-11-23 | Aptinyx Inc. | Spiro-lactam nmda receptor modulators and uses thereof |
US11299495B2 (en) | 2016-08-01 | 2022-04-12 | Aptinyx Inc. | Spiro-lactam NMDA receptor modulators and uses thereof |
EP3490974B1 (en) | 2016-08-01 | 2023-12-06 | Tenacia Biotechnology (Hong Kong) Co., Limited | Spiro-lactam nmda receptor modulators and uses thereof |
SG11201900546UA (en) | 2016-08-01 | 2019-02-27 | Aptinyx Inc | Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof |
EA201990428A1 (en) | 2016-08-01 | 2019-08-30 | Аптиникс Инк. | SPIRALACTAM MODULERS OF NMDA RECEPTOR AND THEIR APPLICATION |
JP2019527232A (en) | 2016-08-01 | 2019-09-26 | アプティニックス インコーポレイテッド | Spiro-lactam NMDA modifier and method using the same |
KR102642063B1 (en) | 2017-02-15 | 2024-03-04 | 카비온, 인코포레이티드 | calcium channel inhibitor |
MX2019012818A (en) | 2017-04-26 | 2020-07-14 | Cavion Inc | Methods for improving memory and cognition and for treating memory and cognitive disorders. |
BR112020015710A2 (en) | 2018-01-31 | 2020-12-08 | Aptinyx Inc. | SPIRAL-LACTAM MODULATORS OF NMDA RECEPTORS AND USES OF THE SAME |
WO2020072773A1 (en) | 2018-10-03 | 2020-04-09 | Cavion, Inc. | Treating essential tremor using (r)-2-(4-isopropylphenyl)-n-(1-(5-(2,2,2-trifluoroethoxy)pyridin-2-yl)ethyl)acetamide |
CA3129827A1 (en) | 2019-02-12 | 2020-08-20 | Mirum Pharmaceuticals, Inc. | Genotype and dose-dependent response to an asbti in patients with bile salt export pump deficiency |
JP2022540253A (en) | 2019-07-11 | 2022-09-14 | プラクシス プレシジョン メディシンズ, インコーポレイテッド | Formulations of T-type calcium channel modulators and methods of use thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5698548A (en) * | 1993-01-21 | 1997-12-16 | Schering Corporation | Spirocycloalkyl-substituted azetidinones useful as hypocholesterolemic agents |
US20050096307A1 (en) * | 2003-11-05 | 2005-05-05 | Schering Corporation | Combinations of lipid modulating agents and substituted azetidinones and treatments for vascular conditions |
Family Cites Families (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4692515A (en) * | 1984-09-24 | 1987-09-08 | Pennwalt Corporation | Adamantane-spirolactams |
US5215994A (en) | 1990-09-25 | 1993-06-01 | Fujisawa Pharmaceutical Co., Ltd. | Angiotenin II antagonizing heterocyclic derivatives |
US5130425A (en) * | 1990-10-12 | 1992-07-14 | American Home Products Corporation | Spiro-lactams and analogs thereof useful as aldose reductase inhibitors |
US5688787A (en) | 1991-07-23 | 1997-11-18 | Schering Corporation | Substituted β-lactam compounds useful as hypochlesterolemic agents and processes for the preparation thereof |
GB9201789D0 (en) | 1992-01-28 | 1992-03-11 | Fujisawa Pharmaceutical Co | Heterocyclic derivatives |
US5354759A (en) | 1991-09-12 | 1994-10-11 | Fujisawa Pharmaceutical Co., Ltd. | Angiotenin II antagonizing heterocyclic compounds |
CA2131184A1 (en) | 1992-04-03 | 1993-10-14 | Jan Willem Hubert Smeets | Selective n-acylation of amino alcohols |
US5631365A (en) | 1993-09-21 | 1997-05-20 | Schering Corporation | Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents |
FR2710337B1 (en) | 1993-09-23 | 1995-12-08 | Gerard Coquerel | Process for the splitting of two optical antipodes by programmed and self-seeded polythermic drive. |
US5633246A (en) | 1994-11-18 | 1997-05-27 | Schering Corporation | Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents |
US5624920A (en) | 1994-11-18 | 1997-04-29 | Schering Corporation | Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents |
US5656624A (en) | 1994-12-21 | 1997-08-12 | Schering Corporation | 4-[(heterocycloalkyl or heteroaromatic)-substituted phenyl]-2-azetidinones useful as hypolipidemic agents |
US5648484A (en) * | 1995-03-07 | 1997-07-15 | Schering Corporation | Catalytic enantioselective synthesis of a spriofused azetidinone |
PT888349E (en) | 1996-01-23 | 2002-10-31 | Novartis Ag | PYRROLOPYRIMIDINES AND PROCESSES FOR THEIR PREPARATION |
US5756470A (en) | 1996-10-29 | 1998-05-26 | Schering Corporation | Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents |
FR2799756B1 (en) | 1999-10-15 | 2001-12-14 | Adir | NOVEL BENZOTHIOPHENIC, BENZOFURANIC AND INDOLIC DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
DE10050322A1 (en) | 2000-10-10 | 2002-04-11 | Brose Fahrzeugteile | Car door module bearer as plate with fixer holes or slots clear of plate sealing surround and plate using hooks as fixers into openings or vice versa. |
WO2002050027A1 (en) | 2000-12-21 | 2002-06-27 | Aventis Pharma Deutschland Gmbh | Novel 1,2-diphenzylazetidinones, method for producing the same, medicaments containing said compounds, and the use thereof for treating disorders of the lipid metabolism |
TWI291957B (en) | 2001-02-23 | 2008-01-01 | Kotobuki Pharmaceutical Co Ltd | Beta-lactam compounds, process for repoducing the same and serum cholesterol-lowering agents containing the same |
EP2335700A1 (en) | 2001-07-25 | 2011-06-22 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis C virus polymerase inhibitors with a heterobicylic structure |
JP2003214113A (en) | 2002-01-28 | 2003-07-30 | Toshiba Corp | Geothermal turbine |
US20040122033A1 (en) | 2002-12-10 | 2004-06-24 | Nargund Ravi P. | Combination therapy for the treatment of obesity |
GB0307891D0 (en) | 2003-04-04 | 2003-05-14 | Angeletti P Ist Richerche Bio | Chemical compounds,compositions and uses |
AR041089A1 (en) | 2003-05-15 | 2005-05-04 | Merck & Co Inc | PROCEDURE AND PHARMACEUTICAL COMPOSITIONS TO TREAT ATEROSCLEROSIS, DYSLIPIDEMIAS AND RELATED AFFECTIONS |
US20070099884A1 (en) | 2003-06-06 | 2007-05-03 | Erondu Ngozi E | Combination therapy for the treatment of diabetes |
US20060148721A1 (en) | 2003-06-06 | 2006-07-06 | Erondu Ngozi E | Combination therapy for the treatment of dyslipidemia |
US7342039B2 (en) | 2003-09-25 | 2008-03-11 | Wyeth | Substituted indole oximes |
US7396940B2 (en) | 2003-10-23 | 2008-07-08 | Hoffmann-La Roche Inc. | Combinatorial library of 3-aryl-1H-indole-2-carboxylic acid |
TW200538453A (en) | 2004-04-26 | 2005-12-01 | Bristol Myers Squibb Co | Bicyclic heterocycles as kinase inhibitors |
ITMI20040874A1 (en) | 2004-04-30 | 2004-07-30 | Ist Naz Stud Cura Dei Tumori | INDOLIC AND AZAINDOLIC DERIVATIVES WITH ANTI-TUMORAL ACTION |
EP1598336A1 (en) * | 2004-05-20 | 2005-11-23 | Laboratorios Del Dr. Esteve, S.A. | Regioselective hydroxylation, functionalisation and protection of spirolactams |
US7291728B2 (en) * | 2004-05-10 | 2007-11-06 | Laboratories Del Dr. Esteve, S.A. | Spirolactams and their synthesis |
EP1771169A1 (en) | 2004-07-14 | 2007-04-11 | PTC Therapeutics, Inc. | Methods for treating hepatitis c |
MX2009002919A (en) * | 2006-09-15 | 2009-04-01 | Schering Corp | Azetidine and azetidone derivatives useful in treating pain and disorders of lipid metabolism. |
MX2009002918A (en) * | 2006-09-15 | 2009-03-31 | Schering Corp | Azetidinone derivatives and methods of use thereof. |
EP2061462A2 (en) * | 2006-09-15 | 2009-05-27 | Schering Corporation | Treating pain, diabetes and lipid metabolism disorders |
WO2008033431A1 (en) * | 2006-09-15 | 2008-03-20 | Schering Corporation | Spirocyclic azetidinone derivatives for the treatment of disorders of lipid metabolism, pain, diabetes and other disorders |
MX2009002922A (en) * | 2006-09-15 | 2009-04-01 | Schering Corp | Azetidine and azetidone derivatives useful in treating pain and disorders of lipid metabolism. |
CN101541795A (en) * | 2006-09-15 | 2009-09-23 | 先灵公司 | Spiro-condensed azetidine derivatives useful in treating pain, diabetes and disorders of lipid metabilism |
-
2007
- 2007-09-13 MX MX2009002921A patent/MX2009002921A/en unknown
- 2007-09-13 CN CNA2007800392504A patent/CN101583612A/en active Pending
- 2007-09-13 JP JP2009528293A patent/JP2010503677A/en not_active Withdrawn
- 2007-09-13 WO PCT/US2007/019930 patent/WO2008033464A2/en active Application Filing
- 2007-09-13 EP EP07838185A patent/EP2061792A2/en not_active Withdrawn
- 2007-09-13 US US11/854,754 patent/US7884080B2/en not_active Expired - Fee Related
- 2007-09-13 CA CA002663502A patent/CA2663502A1/en not_active Abandoned
- 2007-09-14 TW TW096134360A patent/TW200819450A/en unknown
- 2007-09-14 AR ARP070104078A patent/AR063219A1/en not_active Application Discontinuation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5698548A (en) * | 1993-01-21 | 1997-12-16 | Schering Corporation | Spirocycloalkyl-substituted azetidinones useful as hypocholesterolemic agents |
US20050096307A1 (en) * | 2003-11-05 | 2005-05-05 | Schering Corporation | Combinations of lipid modulating agents and substituted azetidinones and treatments for vascular conditions |
Non-Patent Citations (8)
Title |
---|
ALONSO EDUARDO ET AL: "Spiro .beta.-lactams as .beta.-turn mimetics. Design, synthesis, and NMR conformational analysis", JOURNAL OF ORGANIC CHEMISTRY, AMERICAN CHEMICAL SOCIETY. EASTON, US, vol. 66, no. 19, 2001, pages 6333 - 6338, XP002467267, ISSN: 0022-3263 * |
BITTERMANN, HOLGER ET AL: "Chirospecific Synthesis of Spirocyclic .beta.-Lactams and Their Characterization as Potent Type II .beta.-Turn Inducing Peptide Mimetics", JOURNAL OF ORGANIC CHEMISTRY , 71(1), 97-102 CODEN: JOCEAH; ISSN: 0022-3263, 2006, XP002472747 * |
CIGNARELLA G ET AL: "Synthesis of a new series of 2,7-diazaspiro(3.5)nonan-1-ones and study of their cholinergic properties", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, EDITIONS SCIENTIFIQUE ELSEVIER, PARIS, FR, vol. 29, no. 2, 1994, pages 115 - 120, XP002467925, ISSN: 0223-5234 * |
CLAYDEN J ET AL: "Cyclization of lithiated pyridine and quinoline carboxamides: synthesis of partially saturated pyrrolopyridines and spirocyclic beta-lactams", ORGANIC LETTERS, ACS, WASHINGTON, DC, US, vol. 7, no. 17, 18 August 2005 (2005-08-18), pages 3673 - 3676, XP002467924, ISSN: 1523-7060 * |
KHASANOV ALISHER B ET AL: "Novel Asymmetric Approach to Proline-Derived Spiro-.beta.-lactams", JOURNAL OF ORGANIC CHEMISTRY, AMERICAN CHEMICAL SOCIETY. EASTON, US, vol. 69, no. 17, 2004, pages 5766 - 5769, XP002467266, ISSN: 0022-3263 * |
MACIAS, ALBERTO ET AL: "Diastereoselective [2+2]-Cycloaddition Reactions of Unsymmetrical Cyclic Ketenes with Imines: Synthesis of Modified Prolines and Theoretical Study of the Reaction Mechanism", JOURNAL OF ORGANIC CHEMISTRY , 69(21), 7004-7012 CODEN: JOCEAH; ISSN: 0022-3263, 2004, XP002472748 * |
MACIAS, ALBERTO ET AL: "Synthesis of Enantiopure Pyrrolidine-Derived Peptidomimetics and Oligo-.beta.-peptides via Nucleophilic Ring-Opening of .beta.-Lactams", JOURNAL OF ORGANIC CHEMISTRY , 71(20), 7721-7730 CODEN: JOCEAH; ISSN: 0022-3263, 2006, XP002472746 * |
OVERMAN, LARRY E. ET AL: "A convenient synthesis of 4-unsubstituted .beta.-lactams", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY , 107(6), 1698-701 CODEN: JACSAT; ISSN: 0002-7863, 1985, XP002472749 * |
Also Published As
Publication number | Publication date |
---|---|
WO2008033464A2 (en) | 2008-03-20 |
MX2009002921A (en) | 2009-04-01 |
US7884080B2 (en) | 2011-02-08 |
CN101583612A (en) | 2009-11-18 |
JP2010503677A (en) | 2010-02-04 |
EP2061792A2 (en) | 2009-05-27 |
CA2663502A1 (en) | 2008-03-20 |
TW200819450A (en) | 2008-05-01 |
US20080076751A1 (en) | 2008-03-27 |
AR063219A1 (en) | 2009-01-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2008033464A3 (en) | Azetidinone derivatives for the treatment of disorders of the lipid metabolism | |
MX2009002924A (en) | Spirocyclic azetidinone derivatives for the treatment of disorders of lipid metabolism, pain, diabetes and other disorders. | |
WO2006093348A3 (en) | Method and composition for treating peripheral vascular diseases | |
WO2006078463A3 (en) | Method for treating cardiovascular disease | |
WO2007002572A3 (en) | Nattokinase for reducing whole blood viscosity | |
WO2008033460A3 (en) | Treating pain, diabetes, and lipid metabolism disorders | |
WO2007130383A3 (en) | Compositions and treatments using pyridazine compounds and secretases | |
WO2007061661A3 (en) | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | |
WO2007127474A3 (en) | Compositions and treatments using pyridazine compounds and cholinesterase inhibitors | |
WO2007138466A3 (en) | Pharmaceutical compositions comprising meloxicam and tramadol combination | |
WO2008022256A3 (en) | Methods and compositions for preventing or treating age-related diseases | |
WO2008082602A3 (en) | Compounds and pharmaceutical compositions for the treatment of liver disorders | |
MX2013004699A (en) | Pharmaceutical combinations for the treatment of metabolic disorders. | |
EA200900940A1 (en) | PHARMACEUTICAL COMPOSITION CONTAINING PYRAZOL-O-GLUCOSIDE DERIVATIVE | |
EP2331095A4 (en) | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
MX2010001696A (en) | Pharmaceutical composition comprising a glucopyranosyl-substitute d benzene derivative. | |
MX2010001560A (en) | Pharmaceutical composition comprising a sglt2 inhibitor in combination with a dpp-iv inhibitor. | |
WO2005116002A3 (en) | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | |
WO2005072045A3 (en) | The combined use of glp-1 agonists and gastrin for regulating blood glucose levels | |
WO2008157537A3 (en) | Compositions and methods of use for treating or preventing lipid related disorders | |
TW200740452A (en) | Therapeutic gastrodia extracts | |
WO2006108582A3 (en) | Human marker genes and agents for diagnosis, treatment and prophylaxis of cardiovascular disorders and artherosclerosis | |
WO2008097924A3 (en) | Pharmaceutical compositions comprising dextromethorphan analogs for the treatment of neurological disorders | |
WO2007016679A3 (en) | Combination immediate release controlled release levodopa and carbidopa dosage forms | |
WO2008078176A9 (en) | Methods, compounds, and compositions for treating metabolic disorders and diabetes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200780039250.4 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007838185 Country of ref document: EP |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07838185 Country of ref document: EP Kind code of ref document: A2 |
|
ENP | Entry into the national phase |
Ref document number: 2009528293 Country of ref document: JP Kind code of ref document: A Ref document number: 2663502 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2009/002921 Country of ref document: MX |